Treace Medical Concepts, Inc. - Common Stock (TMCI)
10.54
0.00 (0.00%)
Treace Medical Concepts Inc is a medical technology company focused on developing and commercializing innovative solutions for foot and ankle surgery
The company specializes in advanced surgical techniques and devices aimed at improving patient outcomes, particularly in conditions such as bunions and other foot deformities. Treace Medical provides surgeons with minimally invasive products that enhance the precision and efficiency of surgical procedures, ultimately helping patients achieve quicker recovery times and improved mobility. Through ongoing research and development, Treace Medical strives to remain at the forefront of the orthopedic medical device industry.
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing its SpeedAkin™ Anatomic Compression Implant.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · January 30, 2025
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · January 13, 2025
![](https://mms.businesswire.com/media/20250109575722/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
The Law Offices of Frank R. Cruz continues its investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQTMCI) investors concerning the Company and its officers’ possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · January 9, 2025
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · January 2, 2025
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
Positions Treace to Significantly Increase Share of Overall Bunion Market and Expand Surgeon Customer Base
By Treace Medical Concepts, Inc. · Via GlobeNewswire · December 30, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQTMCI) for violations of the securities laws.
Via ACCESSWIRE · December 16, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · December 16, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQTMCI) for violations of the securities laws.
Via ACCESSWIRE · December 15, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQTMCI) for violations of the securities laws.
Via ACCESSWIRE · December 14, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQTMCI) for violations of the securities laws.
Via ACCESSWIRE · December 13, 2024
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQTMCI) for violations of the securities laws.
Via ACCESSWIRE · December 12, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuide™ PSI technology with the Adductoplasty® System for a CT-based, patient specific correction personalized to the patient’s unique midfoot deformity.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · December 4, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace’s commercial efforts and play a pivotal role in driving the Company’s next phase of rapid innovation, strategic product commercialization, and growth.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · December 2, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · November 18, 2024
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQTMCI) on behalf of Treace stockholders. Our investigation concerns whether Treace has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · November 5, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · November 5, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 11:45 am ET.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · November 4, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule, effective January 1, 2025.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · November 4, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
Positions Treace to Significantly Increase Penetration into Overall Bunion Market and Expand Surgeon Customer Base
By Treace Medical Concepts, Inc. · Via GlobeNewswire · November 4, 2024
![](https://mms.businesswire.com/media/20241101090303/en/478343/5/GPM_Logo_Colo.jpg)
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQTMCI) investors concerning the Company’s possible violations of the federal securities laws.
By Glancy Prongay & Murray LLP · Via Business Wire · November 1, 2024
![](https://www.businesswire.com/images/bwlogo_extreme.png)
Law Offices of Howard G. Smith announces an investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQTMCI) investors concerning the Company’s possible violations of federal securities laws.
By Law Offices of Howard G. Smith · Via Business Wire · October 31, 2024
![](https://mms.businesswire.com/media/20241031238711/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
The Law Offices of Frank R. Cruz announces an investigation of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQTMCI) on behalf of investors concerning the Company’s possible violations of federal securities laws.
By The Law Offices of Frank R. Cruz · Via Business Wire · October 31, 2024
![](https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg)
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQTMCI) on behalf of Treace stockholders. Our investigation concerns whether Treace has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · October 28, 2024
![](https://ml.globenewswire.com/media/e6af4ccc-19b1-4fe0-948f-436f2b9d2ea5/small/treace-color-jpg.jpg)
PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
By Treace Medical Concepts, Inc. · Via GlobeNewswire · October 22, 2024
![](https://mms.businesswire.com/media/20241021914317/en/827144/22/Schall-Firm-Logo-640x360.jpg)
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace” or “the Company”) (NASDAQTMCI) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · October 21, 2024